Medicine and Pharmacology

Review
Medicine and Pharmacology
Surgery

Hiroki Ichiba

,

Masaoki Ito

,

Alexander Gregor

,

Hideki Ujiie

,

Yasuhiro Tsutani

Abstract: Background/Objectives: Augmented reality (AR) and virtual reality (VR) are increasingly utilized across the perioperative continuum in thoracic surgery. We performed a systematic review to elucidate the clinical utility of AR/VR technologies in general thoracic surgery, identify current technological trends, and evaluate their role as objective assessment tools for surgical competency. Methods: A comprehensive systematic search of the PubMed database was conducted from inception through 6 June 2026 in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligible peer-reviewed studies were categorized according to their clinical phase of utilization, perioperative surgical outcomes, and objective simulator-derived competency metrics. Results: A total of 1,013 records were initially identified, of which 74 met the inclusion criteria and were analyzed. Clinical applications of AR/VR in thoracic surgery spanned three principal domains: (1) surgical education and training, (2) preoperative anatomical planning and resection simulation, and (3) real-time intraoperative navigation (encompassing non-anatomical tumor localization and anatomical bronchovascular guidance). Integration of artificial intelligence (AI) further accelerated three-dimensional anatomical segmentation and intraoperative registration workflows. Across nine comparative cohort studies, AR/VR or three-dimensional guidance was associated with significantly shorter operative times in 77.8% (7/9) and lower estimated intraoperative blood loss in 55.6% (5/9) of studies without increasing postoperative complications. Furthermore, validated VR simulation platforms reliably stratified novice, intermediate, and experienced surgeons using automated kinematic metrics. Conclusions: AR and VR technologies enhance surgical training, complex segmentectomy planning, and intraoperative navigation. Standardized VR scoring systems incorporating procedural time, simulated blood loss, and instrument motion dynamics are warranted to advance objective surgical credentialing.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Jessica Wen

,

Yuwei Xue

,

Wu Liu

,

Guillem Pratx

Abstract: AGuIX nanoparticles are gadolinium (Gd)-based, sub-5 nm nanoparticles designed for radiosensitization and MRI contrast enhancement. The high atomic number of Gd (Z = 64) enables efficient X-ray absorption and dose deposition within tumors, with tumor accumulation facilitated by the enhanced permeability and retention effect. Previous clinical trials have provided preliminary evidence for the safety and potential therapeutic benefit of intravenous AGuIX in patients with cervical cancer and brain metastases. To improve tumor specificity, we conjugated AGuIX with a pH-low insertion peptide (pHLIP-AGuIX), which targets the acidic tumor microenvironment through pH-dependent membrane insertion. In vitro experiments were performed with cultured A549 human lung adenocarcinoma cells at pH 6.2 (tumor-like) and pH 7.4 (physiologic) conditions. In vivo, mice bearing subcutaneously implanted A549 tumors received 10 Gy X-ray irradiation with or without unconjugated AGuIX or pHLIP-AGuIX pretreatment (300 mg/kg; n = 7 mice/group). Colony formation assays and mass spectroscopy analysis revealed that conjugation of the pHLIP peptide to AGuIX increased intracellular Gd levels approximately 18-fold under acidic conditions compared to unconjugated AGuIX, but without significantly altering cell survival at the tested concentration (0.17 mM). In vivo, all ir-radiated groups exhibited significant tumor growth delay compared to controls (P < 0.01), but no additional radiosensitization was observed in the nanoparticle-treated cohorts, despite detectable Gd tumor accumulation. MRI T1 mapping demonstrated shortened T1 relaxation times following AGuIX administration, with greater reduction following pHLIP-AGuIX injection. These findings suggest that pHLIP conjugation improves Gd uptake and MRI visibility but does not enhance therapeutic efficacy under current conditions. Departing from previous work, this study used a simpler covalent bond to conjugate pHLIP to AGuIX rather than a disulfide bridge, which may explain the decreased efficacy. Reintroducing the disulfide linkage might be critical, as it allows the nanoparticle cargo to break free from its membrane-bound anchor and reach the nucleus.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Renata Andrea Rusu-Patraulea

,

Petronela Rusu

,

Irina Bondei

,

Nicolae Todor

,

Leonard D. Rusu

,

Claudia Burz

,

Zsolt Fekete

,

Tudor E. Ciuleanu

Abstract: Purpose and methods: We aimed to evaluate in rw pts, the safety profile, effectiveness and prog-nostic factors associated with the RR, PFS, and secondarily, OS of durvalumab, after c/sCRT, without progression, in LA NSCLC, PD-L1 ≥ 1%. Durvalumab was administered 10 mg/kg at 2 weeks or monthly 1500 mg iv, until disease progression or unacceptable toxicity, no more than a year. Results: Eligible were 75 pts with LA NSCLC, PD-L1 ≥ 1%, but 10 (13.3%) progressed after CRT, thus evaluated were 65 pts. Discontinuation of durvalumab occurred in 23% due to grade ≥ 3 adverse events and in 23% for disease progression. DC in 60% was associated significantly by PS, NC, NLR and AS only approached the significance level. PFS of 30% at 2 years, with a median value of 18 months, was significantly associated with age, PS, NC, NLR, AS. In the multivariable analysis significant prognostic factor remained PS and AS approached significance level. OS of 55% at 2 years and mOS was 26.1 months. Conclusions: Durvalumab after CRT in rw pts with LA NSCLC demonstrate a good safety profile, promising RR, PFS and OS, consistent with other rw analyses. Age, PS, AS, NC, NLR, were associated significantly with PFS. PS remained significant prognostic factors, in the multivariable analysis. AS only approached the significance level war-ranting further investigations concerning the role of psychological profile and support in LA NSCLC.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Cheng Hu

Abstract: Background. Abdominal aortic aneurysm (AAA) is managed by a diameter threshold, yet 61% of ruptures in contemporary cohorts occur below 55 mm and diameter-matched cohorts of ruptured and unruptured aneurysms show no difference in diameter. Existing computational approaches quantify the wall stress at a given instant but not the cumulative mechanical history of the wall. We tested whether AAA can be reproduced as a fatigue-failure process of elastin, with a discrete transition — damage exposure — separating a purely mechanical phase from a biologically amplified one. The resulting framework rests on two load-bearing components with opposed duties, a discrete exposure transition, and a five-stage progression in which compensation itself fails.Methods. We constructed a two-layer model (the Damage-Exposure Model, DEM) comprising four global state variables — elastin, collagen, junction protein and inflammation — and a 720-point circumferential spatial layer carrying wall thickness, local strength and thrombus coverage. Elastin-specific local stress was compared with elastin-specific local strength. Parameters were assigned to three tiers: 23 measured in the literature, 5 derived from literature values, and 15 calibrated to reproduce specified targets. The model was run for 76 patients whose transcriptomic module scores were mapped to individual mechanical parameters, and against seven external comparisons, three pre-specified testable inferences and a 500-run Monte Carlo analysis.Results. The model reproduces a five-stage progression at ages 20.0, 56.7, 58.7, 66.6 and 73.5 years, a rupture diameter of 55.76 mm, and a two-phase expansion pattern (36.7 years before the transition, 16.8 years after). In the 76-patient cohort, 61% of simulated ruptures occurred below 55 mm and the median rupture age was 71.5 years, against 74.0 years in a 3,642-patient national registry. Of seven external comparisons, one is an independent test, four are calibration-consistency checks and two are not valid comparisons. Of the three testable inferences, one is true by construction rather than empirically, one is contradicted by the data, and one has no discriminating power. Only 4.2% of 500 Monte Carlo parameter draws satisfied five or more of the seven comparisons.Conclusions. A fatigue-based model of elastin depletion with a discrete exposure transition reproduces the timing, the rupture diameter and the sub-threshold rupture fraction of AAA, and explains why diameter alone discriminates poorly between ruptured and unruptured aneurysms. The model is not validated: its time scale is dominated by a single calibrated parameter and fifteen parameters are not identifiable. It should be read as a quantitatively specified hypothesis with an explicit falsification path, not as a clinical prediction tool.

Review
Medicine and Pharmacology
Medicine and Pharmacology

Richard Z. Cheng

Abstract: Inflammation is an adaptive biological response whose persistence can reflect interacting metabolic, nutritional, environmental, endocrine, immune, and behavioral conditions. Laboratory markers sample different aspects of this process and require interpretation alongside disease activity, organ function, and clinical outcomes. This narrative review develops an Integrative Orthomolecular Systems Medicine (I-OM) framework for assessment and intervention. It classifies conventional and specialty measurements by biological domain, distinguishes assay availability from analytical validity and clinical utility, and separates biological half-life, first response, normalization, and retesting. ESR and CRP serve as principal examples; immune, intestinal, vascular, and oxidative-damage measurements provide complementary information for selected questions. Human intervention evidence is reviewed for carbohydrate restriction, nutritional ketosis, fasting, dietary quality, orthomolecular nutrients, periodontal care, endocrine treatment, and behavioral support. Results vary by population, comparator, baseline status, exposure, and endpoint. Intermittent ketogenic mechanisms are distinguished from human efficacy, and exposure reduction is separated from unvalidated detoxification claims. Cheng’s Six Principles of Good Medicine, Ten Root Drivers, nutrient principles, and Triple-Principle Intervention Model connect the evidence to cause-oriented assessment and physiological restoration. The proposed integration prioritizes symptoms, function, organ health, safety, affordability, and appropriately selected biomarkers. It provides an evidence-informed perspective and a testable research framework; the incremental clinical benefit of the integrated I-OM program has not been established.

Review
Medicine and Pharmacology
Pharmacy

Edoardo De Luigi

,

Lucrezia Greta Armando

,

Gianluca Miglio

,

Clara Cena

Abstract: Background: Population ageing, prevalence of multimorbidity, polypharmacy and frailty considerably increase the complexity of pharmacological treatment in older adults and the risk of medication-related harm. Medication review (MR) represents a key strategy to assess treatment appropriateness, support medication optimization and identify opportunities for deprescribing. However, its implementation in routine clinical practice remains heterogeneous and inconsistent. Methods: A narrative review was conducted focusing on MR conceptual framework, assessment and deprescribing tools, interprofessional collaboration, implementation strategies, and emerging artificial intelligence (AI)-supported technologies across different healthcare settings. Relevant literature was identified through searches on PubMed, Google Scholar and Scopus, complemented by reference-list screening and citation tracking. Recent literature was prioritized, while seminal publications and guidelines were retained when relevant to the development of key concepts. Results: MR encompasses different approaches, ranging from structured medication assessment to comprehensive holistic processes incorporating clinical judgement and shared decision-making. Explicit and implicit tools can support the identification of potentially inappropriate medications and other drug-related problems, while deprescribing approaches facilitate the reassessment and discontinuation of unnecessary medications. Evidence also highlights the importance of pharmacists and interprofessional collaboration, patient involvement, workflow integration, and organizational support for successful implementation. Digital and AI-based approaches, including electronic health record-integrated clinical decision support systems, may further support medication optimization. Conclusions: MR should be considered a dynamic and collaborative process rather than a one-time assessment of medication lists. Future efforts should focus on its sustainable integration into routine care, continuity across healthcare settings, standardized implementation strategies, and the validation of digital tools that complement clinical judgement.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Josephine Kranendonk

,

Suzanne Holewijn

,

Lars L.F.G. Valke

,

Cornelis Kramers

,

Michiel C. Warlé

,

Michel M.P.J. Reijnen

,

Houshang Monajemi

Abstract: Background/objective: To investigate the association between lipoprotein(a) (Lp(a)) concentrations, peripheral arterial disease (PAD), and the occurrence of major adverse cardiovascular events (MACE), or major adverse limb events (MALE). Methods: This prospective single center cohort study included 475 patients referred to a vascular center with suspected PAD de novo between January 13th 2017 and December 27th 2019. Serum Lp(a) concentrations were measured at baseline, and electronic patients’ records were reviewed for diagnosis of PAD at baseline, and the occurrence of MACE or MALE during follow-up. MACE was defined as a composite of myocardial infarction, unplanned percutaneous coronary intervention, ischemic cerebrovascular accident, transient ischemic attack, and cardiovascular death. MALE was defined as any endovascular or open revascularization or limbrelated vascular intervention performed due to PAD. Results: Of the 475 patients, 332 patients (69.9%) were diagnosed with PAD. Patients with PAD had significantly higher median LP(a) concentrations compared to those in whom PAD was ruled out (30 [11-77] mg/dL versus 19 [9-64] mg/dL, p=0.033), without differences in other lipid parameters. During a median follow-up of 6 years, 81 patients with PAD (24.4%) experienced MACE, and 141 patients (42.5%) experienced MALE. Univariate cox regression analysis showed that serum Lp(a) concentration was not significantly associated with MACE (HR 0.909, p=0.206), nor MALE (HR 1.000, p=0.995) in patients with PAD. Multivariate cox regression showed similar results. Conclusion: Patients who were diagnosed with PAD de novo had significantly higher Lp(a) concentrations, but Lp(a) was not significantly associated with occurrence of MACE or MALE.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Tânia Rodrigues

,

Luís Mascarenhas-Lemos

,

Joana Cardoso

,

Ivo Sousa-Ferreira

,

João Paulo Martins

,

Ana Faria

,

Mariana Câmara

,

Rui Maio

,

José Passos Coelho

Abstract: Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited prognostic biomarkers after curative-intent resection. We aim to determine if loss of SMAD4 protein expression has prognostic significance in operated PDAC patients. Methods: SMAD4 protein expression was evaluated by immunohistochemistry (IHC) in resected PDAC tu-mours from patients treated at two centers. The prognostic significance of SMAD4 expression status and clinical outcomes, namely overall survival (OS) and recurrence-free survival (RFS), was assessed using survival analysis with Kaplan–Meier estimation and Cox proportional hazards regression models. Results: A total of 87 patients with resected PDAC were included in the final analysis, with a median follow-up of 75.9 months. In univariable analysis, SMAD4 expression status was not associated with OS (intact vs. lost: HR = 0.87, p = 0.56) or RFS (HR = 0.84, p = 0.51). In multivariable analysis, SMAD4 expression was not an independent prognostic factor for OS (HR = 0.94, p = 0.81) or RFS (HR = 0.82, p = 0.49). Established clinicopathological variables, including histological grade, nodal status, postoperative CA19-9 levels, and adju-vant treatment, were independently associated with both survival outcomes, while resection status was inde-pendently associated with OS. Conclusions: In this bicentric cohort, loss of SMAD4 expression assessed by IHC was not an independent prognostic marker for OS or RFS of resected PDAC. Despite the potential SMAD4 relevance within specific biological or clinical subgroups, further studies are warranted to clarify the role of SMAD4 in PDAC risk strati-fication and support the development of integrated molecular and clinicopathological prognostic models.

Case Report
Medicine and Pharmacology
Emergency Medicine

Fujian Wang

,

Rong Yao

,

Shu Zhang

Abstract: Mechanical tricuspid prosthetic valve obstruction is a rare but potentially life-threatening complication of prosthetic valve replacement. It typically presents with right-sided heart failure or systemic venous congestion, whereas refractory hypoxemia as the predominant manifestation is uncommon. We report the case of a 34-year-old man who underwent mechanical tricuspid valve replacement 10 years earlier for infective endocarditis, tricuspid valve vegetation, and severe tricuspid regurgitation. He was admitted with sudden-onset dyspnea. Despite endotracheal intubation and invasive mechanical ventilation with a fraction of inspired oxygen (FiO₂) of 100%, peripheral oxygen saturation remained at 60%–82%, and the arterial partial pressure of oxygen (PaO₂) was 43.7 mmHg. Chest imaging showed no pulmonary parenchymal or vascular abnormalities sufficient to account for the severity of hypoxemia. Transthoracic echocardiography showed abnormal motion of one leaflet of the mechanical tricuspid prosthesis, with a peak transvalvular velocity of 2.6 m/s and a mean transvalvular pressure gradient of 13 mmHg; however, no definite intracardiac right-to-left shunt was identified. Subsequent transesophageal echocardiography showed that the anterior leaflet of the mechanical prosthesis was fixed in a semi-open position and identified an approximately 5-mm communication at the fossa ovalis with marked right-to-left shunting at the atrial level. Emergency surgery revealed extensive thrombus and pannus formation around and beneath the mechanical prosthesis, restricting leaflet motion. Following replacement of the mechanical tricuspid prosthesis with a bioprosthetic valve and closure of the patent foramen ovale, oxygenation rapidly returned to normal. This case suggests that prosthetic valve obstruction associated with intracardiac right-to-left shunting should be considered when severe hypoxemia is disproportionate to pulmonary imaging findings, particularly in the presence of abnormal prosthetic tricuspid leaflet motion or transvalvular hemodynamics. Transesophageal echocardiography permits concurrent assessment of prosthetic valve motion, interatrial septal anatomy, and shunt direction and may provide additional diagnostic information in such complex cases.

Article
Medicine and Pharmacology
Cardiac and Cardiovascular Systems

Praveen Kumar-M

,

A.J. Venkatakrishnan

,

Marcelo Montorzi

,

C. Michael Gibson

,

Venky Soundararajan

Abstract: Importance: In the Lp(a)HORIZON trial, pelacarsen lowered lipoprotein(a) [Lp(a)] by 78% at 12 months without reducing major adverse cardiovascular events (MACE). The neutral result raises the question of whether the cardiovascular risk associated with elevated Lp(a) in routine-care is sufficiently large to yield detectable clinical benefit in ongoing clinical trials. Objective: To quantify the association of Lp(a) with recurrent MACE and aortic valve outcomes in routine care, and to explore the implications of these associations for treatment-benefit scenarios in completed and ongoing Lp(a)-lowering trials. Design, Setting, and Participants: The study used a federated analysis of deidentified electronic health records across participating US academic medical centers. The primary retrospective cohort study analyzed adults aged 18 to 80 years with at least one Lp(a) measurement in routine care and documentation of a prior myocardial infarction, ischemic stroke, or symptomatic peripheral artery disease as of January 1, 2017 or later. Patients were followed for up to 5 years after meeting all inclusion criteria. Exposure: Baseline Lp(a), categorized as high (at least 150 nmol/L or 70 mg/dL) or low (less than 75 nmol/L or 30 mg/dL), and assessed continuously, including analyses stratified by baseline low-density lipoprotein cholesterol (LDL-C) level. Main Outcomes and Measures: Major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, ischemic stroke, or urgent coronary revascularization, and aortic stenosis or valve replacement, with hazard ratios (HRs) derived from adjusted Cox models. Results: Among 13,894 eligible patients, 13,865 contributed follow-up to outcome analyses. MACE occurred in 412 of 3,138 patients with high and 972 of 8,200 with low Lp(a) (5-year cumulative incidence, 20.1% vs 18.3%). The adjusted HR was 1.11 (95% CI, 0.98–1.25) after adjustment for age, sex, race, ethnicity, calendar year of entry, prior care, diagnosis frequency, and type and timing of the qualifying event. There was no consistent evidence of effect modification by LDL-C. In contrast, high Lp(a) was associated with aortic stenosis or valve replacement (HR, 1.62; 95% CI, 1.11–2.36). Under the assumption that pharmacological Lp(a) lowering modifies the risk represented by the observational association, a model-based analysis yielded an illustrative HR of 0.95 (95% CI, 0.89–1.02) for the magnitude of Lp(a) reduction achieved in Lp(a)HORIZON. This estimate was compatible with the reported trial HR of 1.02 and represented a smaller benefit than the trial was powered to detect. Using trial-aligned routine-care cohorts, we then projected the treatment effects for ongoing phase 3 trials of olpasiran and lepodisiran, two Lp(a) lowering agents, based on the approximately 95% reduction in Lp(a) reported in their corresponding phase 2 trials. Under three different assumptions about the timing of clinical benefit, the modeled treatment HRs ranged from 0.94 to 0.98 for OCEAN(a)-Outcomes and 0.89 to 0.97 for ACCLAIM-Lp(a). Conclusions and Relevance: In this multicenter routine-care cohort, elevated Lp(a) showed a modest and statistically insignificant association with recurrent MACE, in contrast to a stronger association with aortic stenosis or valve replacement. Modeled projections based on the observed associations suggested that ongoing trials may not be powered to detect the estimated cardiovascular benefits of Lp(a) reduction. However, these projections do not establish the treatment effects of olpasiran or lepodisiran. The findings highlight the importance of trial population, treatment duration, and clinical endpoint selection, while supporting prospective evaluation of Lp(a)-lowering therapies for aortic valve disease.

Review
Medicine and Pharmacology
Surgery

Mehmet Mahir Ozmen

,

Begum Kocaturk

,

Natale Calomino

,

Luigi Marano

,

Fusun Ozmen

Abstract: Excess adiposity causes at least 13 cancers, and metabolic bariatric surgery (MBS) is increasingly presented as cancer-preventive. We appraised the evidence linking obesity, intentional weight loss and cancer against the Bradford Hill viewpoints, integrating literature published up to October 2026, including the IFSO GRADE-based position statement and a Nordic cohort of 784,105 adults. The obesity–cancer association fulfils the criteria of strength, consistency, biological gradient, temporality and plausibility. After MBS, matched cohorts and meta-analyses consistently report a 20–35% lower incidence of obesity-associated cancers, most clearly for endometrial, ovarian and liver cancer, and the Nordic cohort confirmed a 19% reduction irrespective of age or sex. However, no randomised trial has measured cancer incidence after MBS, certainty is low to very low, and oesophageal, gastric, pancreatic and prostate cancers show neutral or unfavourable signals. Incretin therapy appears protective in observational data but neutral in randomised trials. For surgical oncologists, altered anatomy delays the diagnosis of upper gastrointestinal cancer and changes reconstructive options. The protective association is real, coherent and site-specific but not yet proven causal; it should be discussed as an additional benefit in eligible patients, never as a stand-alone indication.

Article
Medicine and Pharmacology
Neuroscience and Neurology

Anton Bershak

,

Lyudmyla Antypenko

,

Svitlana Koptieva

,

Natalia Bohdan

,

Igor Belenichev

,

Nina Bukhtiyarova

,

Iryna Halabitska

,

Pavlo Petakh

,

Oleksandr Kamyshnyi

,

Sergiy Okovytyy

+1 authors

Abstract: The benzo[f][1,2,4]triazino[2,3-d][1,4]diazepine-2,7(6H,8H)-dione system fuses the 1,4-benzodiazepine framework to a nitrogen-rich triazinone ring, and no member has been evaluated pharmacologically. We asked whether the series is centrally active in rats and whether the scaffold is accommodated at the receptor’s benzodiazepine site. Forty-seven derivatives were docked blind against eight human GABAA receptor cryo-electron microscopy structures and profiled with SwissADME and ProTox-3.0. Six members of series 1 were prepared, four as regioisomer mixtures quantified by two methods. Male Wistar rats (n = 10 per group) received a nominal 10 mg/kg intragastrically, delivering 7.1–9.9 mg/kg of the major regioisomer, in the thiopental-induced sleep test and a predator-odour model of post-traumatic stress disorder. Five compounds prolonged thiopental-induced sleep by 30.6–72.2%, and 1.5 and 1.7 shortened sleep-onset latency by 32.4% and 31.1%. Stress reduced cortical GABA 3.65-fold; 1.5 restored it to a level indistinguishable from intact animals. All compounds except 1.1 raised the cortical serotonin transporter Slc6a4, which diazepam did not. Docking identified a C-3 aryl substituent as the dominant affinity determinant, and 1.1, the only C-3 methyl compound tested, was least active in all three readouts. Members of this series are therefore centrally active in rats, with GABAergic and serotonergic components; benzodiazepine-site mediation remains a docking-based hypothesis.

Review
Medicine and Pharmacology
Ophthalmology

Caitlin Wan Sze Por

,

George Naveen Thomas

,

Victor Teck Chang Koh

,

Dinesh Kumar Srinivasan

Abstract: The retina is a specialised neurovascular–immune–metabolic tissue whose high metabolic demands make it vulnerable to systemic metabolic and inflammatory disturbances. Retinal immunometabolism provides a framework for understanding how mitochondrial dysfunction, oxidative stress, metabolic reprogramming, endothelial injury, and chronic inflammation contribute to retinal pathology. This narrative review critically examines the molecular mechanisms linking retinal immunometabolic dysfunction with cardiometabolic diseases, including diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), hypertension, atherosclerosis, and heart failure, alongside ageing and neurodegeneration. We distinguish established retinal manifestations from emerging associations and experimental mechanisms, highlighting challenges in causality and disease specificity. Advances in retinal imaging, artificial intelligence (AI), oculomics, single-cell transcriptomics, spatial metabolomics, and multi-omics integration offer opportunities for biomarker discovery and disease monitoring. Emerging immunometabolic, senotherapeutic, mitochondrial-targeted, and regenerative interventions also present therapeutic potential, although clinical evidence remains limited. Further mechanistic validation, methodological standardisation, and prospective longitudinal studies are essential to establish clinical utility. Integrating molecular insights with retinal imaging may position the retina as a complementary platform for systemic disease assessment and precision medicine.

Article
Medicine and Pharmacology
Pharmacy

Durga Ramani Sivadasan

,

Tamilselvan Natarajan

,

Ahmad Salawi

,

Vijaya Raghavan Chellan

,

Habibur Rahman

,

Karthik Siram

,

Prasanth Kalavalarasariel Gopinathapillai

,

Arjunan Karuppaiah

Abstract: In brain drug delivery, the BBB (Blood-Brain Barrier) has been a significant barrier for various active pharmaceutical drugs. Therefore, there is an urgent need to develop suitable drug delivery systems. However, the present study aimed to develop a polysorbate-80 (PS-80) coated galantamine (GAL) loaded chitosan nanoparticles (CS-NPs) with particles less than 200 nm to enhance the drug internalization in the brain. GAL-CS-NPs were prepared using the ionic gelation technique and optimized to obtain a particle size of less than 200 nm and further coated with PS-80 to obtain polysorbate-80-coated galantamine-loaded chitosan nanoparticles (PS-80-GAL-CS-NPs). The physiochemical properties of uncoated GAL-CS-NPs, PS-80-coated GAL-CS-NPs, and the in vitro evaluations, such as cytotoxicity and cellular internalization in SH-SY-5Y human neuroblastoma cell lines, were studied. The particle size of optimized PS-80-GAL-CS-NPs was observed to be 115±4 nm, and zeta potential was found to be 31.2±1.7 mV. While the drug entrapment efficiency was found to be 65.5±1.2%. The in vitro drug release of PS-80-GAL-CS-NPs was found to be 56.75±1.3%. However, the cytotoxicity studies did not show any toxicity for the drug concentrations of 10 and 100 µg/mL. PS-80-GAL-CS-NPs facilitated time-dependent GAL uptake in SH-SY-5Y cell lines. Studies conducted in-vivo in plasma revealed a steady release of GAL from PS-80-GAL-CS-NPs. The distribution of PS-80-GAL-CS-NPs in the brain after oral administration at the 1st, 4th, and 8th hours was found to be 1.7, 3.1, and 2.0 times higher when compared to the uncoated NPs. Further, the histopathological study did not show any morphological changes in the rat brain. This study indicates that PS-80-GAL-CS-NPs might be a promising delivery method for Alzheimer’s disease (AD).

Review
Medicine and Pharmacology
Endocrinology and Metabolism

Anssi H. Manninen

Abstract: Body recomposition – the simultaneous gain of fat-free mass (FFM) and loss of fat mass (FM) – remains a central goal in applied sports nutrition, yet the literature is often constrained by an energy-balance paradigm that conflates thermal energy (kcal) with physical mass fluxes. This review offers a mechanistically grounded alternative. I formalize body recomposition using an open-system mass-balance framework, explicitly defining the atomic fluxes of carbon, hydrogen, oxygen, and nitrogen. I then synthesize the mechanistic drivers of recomposition, clarifying the permissive rather than directly stimulatory role of insulin. Building on this foundation, I propose a dietary continuum comprising three archetypes: the VAT-Maximizing (Ketogenic) model, the Anabolic-Maximizing (Carb-Driven) model, and the Pragmatic Recomp (Adherence-Optimized) model. Crucially, I resolve the apparent tension between these models by demonstrating that nitrogen balance and mechanical loading are the universal primary drivers. The archetypes differ not in direct biochemical efficiency, but in how they support training volume, appetite control, and long-term adherence (realized cumulative stimulus). I conclude by proposing testable predictions, a standardized measurement protocol, and practical implementation guidelines for scaling training volume across the continuum.

Article
Medicine and Pharmacology
Epidemiology and Infectious Diseases

Ajete Aliu-Bejta

,

Lindita Ajazaj-Berisha

,

Ilir Bejta

,

Donjeta Hajdari

Abstract: Fungal co-infections are increasingly reported in hospitalized COVID-19 patients; but their clinical significance remains uncertain. We conducted a retrospective cohort study of 3373 hospitalized patients with COVID-19 to evaluate the association between fungal isolates and in-hospital mortality. Fungal isolates were identified in 197 (5.8%) patients, predominantly from respiratory specimens, with non-albicans Candida species accounting for most isolates. Patients with fungal isolates were older, had longer hospital stays, and exhibited higher rates of comorbidities, intensive care use, and exposure to broad-spectrum antibiotics, corticosteroids, and tocilizumab. In-hospital mortality was higher among patients with fungal isolates (18.8% vs. 12.2%, p=0.009). However, in multivariable logistic regression analysis, fungal isolates were not independently associated with mortality (adjusted OR 1.49, 95% CI 0.97-2.29). Mortality was independently associated with age, chronic kidney disease, immunosuppression, and treatment-related factors. These findings suggest that fungal isolates are more likely markers of disease severity and treatment exposure rather than direct contributors to mortality.

Article
Medicine and Pharmacology
Medicine and Pharmacology

Lamyae Yachi

,

Brahim Mojemmi

,

Khalid Karrouchi

,

Mustapha Bouatia

Abstract: Background: Elemental impurities (EIs) in pharmaceutical products may originate from active pharmaceutical ingredients, excipients, manufacturing equipment, utilities, and packaging materials. The ICH Q3D guideline provides a risk-based framework for evaluating and controlling these impurities according to their permitted daily exposure (PDE). This study aimed to perform a comprehensive assessment of elemental impurity risks in an oral solid dosage form using the ICH Q3D component approach (Option 2b), complemented by a quality risk assessment of manufacturing equipment. Methods: The elemental impurity risk assessment was performed using the component approach (Option 2b), considering the active pharmaceutical ingredient (API), four pharmaceutical excipients, manufacturing equipment, primary packaging, and purified water. Supplier data and available analytical results were used to estimate the daily contribution of Class 1 elements (Cd, Pb, As, and Hg) and Class 2A elements (Co, V, and Ni). The calculated patient exposure was compared with the corresponding oral PDE values established by ICH Q3D. Manufacturing equipment was additionally evaluated using Failure Mode and Effects Analysis (FMEA) to identify potential failure modes and assess the effectiveness of existing control measures. Results: The API showed consistently low concentrations of the investigated elemental impurities, with values ≤0.1 µg/g across three independent batches. The assessment of the four excipients indicated no intentional addition of the investigated elemental impurities and low overall contributions to patient exposure. Manufacturing equipment presented a negligible residual risk following the implementation of GMP controls, including equipment qualification, cleaning procedures, preventive maintenance, and visual inspection. The estimated total daily exposures were 0.27, 0.27, 0.27, 0.28, 0.29, 0.32, and 1.66 µg/day for Cd, Pb, As, Hg, Co, V, and Ni, respectively. These values corresponded to 5.4%, 5.4%, 1.8%, 0.9%, 0.58%, 0.32%, and 0.83% of their respective PDEs, all remaining well below the 30% PDE threshold used for the control strategy. Primary packaging and purified water were also considered negligible contributors. Conclusion: The ICH Q3D component approach (Option 2b), combined with systematic quality risk management of manufacturing equipment, provided a practical and scientifically justified framework for elemental impurity assessment in the investigated oral solid dosage form. The estimated exposures were substantially below the applicable PDE values, supporting the adequacy of the existing control measures and indicating that no additional elemental impurity-specific controls were required. This approach may support efficient risk-based decision-making and routine pharmaceutical quality management when reliable supplier and process data are available.

Article
Medicine and Pharmacology
Oncology and Oncogenics

Pantelie Nicolcescu

,

Maria Filofteia Mercuț

,

Ionela Mihai

,

Mihai Rusu

,

Adrian Hașegan

Abstract: Background/Objectives: Blood-count inflammatory indices may mark aggressive renal cell carcinoma (RCC), but their association with adverse pathology may reflect tumour size, anaemia or C-reactive protein (CRP). Methods: In a retrospective cohort of patients undergoing nephrectomy for RCC (2016–2025), five preoperative indices were related to pT3–4 stage and grade 3–4 in models fitted in the same patients, with adjustment for haemoglobin, tumour size (spline) and CRP, multiple imputation and assessment of incremental value. Results: Of 256 patients, 55/232 had pT3–4 and 71/235 grade 3–4 tumours. Per 1-SD increase in log systemic immune-inflammation index (SII), the odds ratio for pT3–4 was 2.21 (1.41–3.47) after adjustment for haemoglobin and size, 2.01 (1.07–3.76) with CRP added (137 patients) and 1.97 (1.27–3.05) after imputation. Adding SII to a model with tumour size increased the optimism-corrected AUC from 0.75 to 0.78. No leucocyte-based index was associated with grade after adjustment for haemoglobin. Conclusions: SII was associated with locally advanced RCC independently of tumour size, haemoglobin and CRP, but added little discrimination once tumour size was known. Validation against radiological staging is required.

Review
Medicine and Pharmacology
Endocrinology and Metabolism

Kaige Li

,

Jibira Yakubu

,

Amit V. Pandey

Abstract: Developing steroidogenesis-directed treatments for polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome (PCOS), requires reducing pathological androgen excess while preserving adrenal and ovarian function. The Cytochrome P450 enzyme CYP17A1 offers a compelling pharmacological target, but its dual 17α-hydroxylase and 17,20-lyase activities complicate selective targeting. This critical narrative review integrates CYP17A1 enzymology with ovarian–adrenal steroidogenesis, peripheral androgen activation and the pharmacology of synthetic inhibitors and natural products. We examine how substrate availability, P450 oxidoreductase, cytochrome b5 and tissue context influence the CYP17A1 catalytic activity and apparent inhibitor selectivity. AKR1C3-dependent androgen activation, 11-oxygenated androgens and neuroendocrine regulation provide complementary perspectives on treatment response. Across candidate interventions, biochemical inhibition, altered enzyme expression and reduced circulating testosterone represent distinct findings; none alone establishes clinically useful target engagement or therapeutic benefit. Selected natural products, including dihydrotanshinone and curcuminoids, provide biochemical evidence of steroidogenic enzyme modulation, whereas clinical studies of botanical preparations remain insufficient to establish CYP17A1-mediated efficacy. Experience with synthetic inhibitors further demonstrates that preferential lyase inhibition cannot be assumed to preserve adrenal or reproductive function. We propose a translational evaluation framework combining direct activity measurements, steroidogenic selectivity panels, assay-interference controls, exposure assessment and endocrine and reproductive safety with patient-relevant outcomes. CYP17A1-directed treatment remains investigational in PMOS/PCOS. Its clinical promise depends on demonstrating a therapeutic window that improves androgen-related symptoms or reproductive outcomes without compromising essential steroid physiology.

Article
Medicine and Pharmacology
Ophthalmology

Hanan Khalid Mofty

,

Weaam Abdullah Alrashed

,

Khalid Fahad Jamous

,

Mansour Mohammad Almufarrej

,

Murad Omar Almomani

,

Abdulrahman Faisal Albloushi

,

Kholoud Ahmed Bokhary

Abstract: Background/Objective: This study aimed to compare the effect of different auditory conditions on visual pathway transmission among patients with type 2 diabetes mellitus (DM) with and without mild non-proliferative DR (NPDR), and to evaluate changes in pattern-reversed visual evoked potential (PVEP) amplitude and latency. Methods: This is a repeated-measures study design with a fixed baseline and randomized order of the two auditory conditions. Adults with DM with and without mild NPDR, aged between 30 and 60 years, were recruited. All participants underwent comprehensive visual and ocular assessment, including Best-Corrected Visual Acuity (BCVA), slit-lamp examination, Optical Coherence Tomography (OCT), screening Pure-Tone Audiometry (PTA), and a pattern-reversal visual evoked potential (PVEP) test conducted under three auditory conditions: silence, Quran recitation, and classical music. P100 amplitude and latency were recorded using both 1° and 0.25° stimulation sizes. Statistical analysis was performed using non-parametric tests and logistic regression analyses adjusted for age and PTA. Results: A total of 38 patients with DM (n=23 without DR and n=15 with mild DR) were included. Eyes with mild NPDR demonstrated significantly reduced P100 amplitude at the 1° stimulus size (χ² = 8.467, p = 0.015) and a significant reduction at 0.25° in both groups (with and without DR) with χ² = 16.478, P < 0.001 and χ² = 33.800, P &lt; 0.001, respectively. Multivariable logistic regression identified the highest association between P100 amplitude at 1° and classical music condition as an independent predictor of NPDR after adjustment for age and PTA (adjusted OR = 2.756, 95% CI: 1.739–4.369; P < 0.001). Conclusions: PVEP amplitude was sensitive to auditory modulation in DM, particularly in those with NPDR. These findings suggest that auditory-modulated PVEP may enhance the prediction of visual pathway transmission reduction associated with DR.

of 1,190